Buy IBRX by Apr 20, 2026.

ImmunityBio has completed a trial to prevent cancer in Americans with Lynch Syndrome. Next week, Dr. PPS will update on bladder cancer talks with the FDA and our NK cell studies—scaling billions for off-the-shelf use. IBRX AI-powered robots efficiently produce m-CENK cells, helping lower costs of therapies like CART and making immunotherapy more accessible. The Bioshield platform is progressing despite challenges.